Lek Pharmaceuticals, a subsidiary of Sandoz Pharmaceuticals, has initiated the construction of a new high-tech biopharmaceutical production centre in Lendava, Slovenia, to expand its biosimilar production capabilities. The new facility is the first among three planned for the Lek site in Lendava. It will generate energy products for existing production and support a future centre for producing drug substances for , targeting treatments in rheumatology, oncology and immunology.
Lek entered into a memorandum of understanding (MoU) with the Slovenian government for the construction of the facility in March 2023, committing to an investment of $400m. The investment in the facility is the largest of its kind in Slovenia. This initial phase of development is part of a broader investment plan to expand production capabilities at the Lendava site.
The groundbreaking on the facility took place in December 2023. The facility’s completion and operational status are anticipated by the end of 2026. The new facility is projected to generate up to 300 new high-value-added positions.
Location Lek Pharmaceuticals’ new biosimilar production facility is located at Trimlini 2D, 9220 in the city of Lendava. The selection of the city for expansion was based on its developmental potential and strategic location near the borders of four countries. Lek Pharmaceuticals’ biosimilar production facility details The centre will cover an area of 40,000m (430,556ft ) and include state-of-the-art facil.